American Vanguard (AVD) Q4 2025 earnings summary

Executive summary

• Adjusted EBITDA for 2025 was $39.2 million, nearly flat year-over-year, slightly above the prior year but below target due to sluggish Q4 sales.

• Net sales declined to $515 million in 2025, down 6% from $547 million in 2024, reflecting continued agricultural market weakness.

• Cost-saving initiatives, including rationalizing the Los Angeles facility and relocating headquarters, are expected to save $4.5 million annually.

• Flexible financing was secured with two new term loans totaling $285 million, replacing the revolving credit facility and enhancing liquidity without equity dilution.

• All material weaknesses from the 2024 audit were remediated.

Financial highlights

• Gross profit margin improved to 29% in 2025 from 22% in 2024, with gross profit rising to $147.6 million.

• Operating expenses decreased, with reductions in transformation and product liability costs.

• Cash at year-end was $12.4 million, nearly unchanged from $12.5 million in 2024.

• Adjusted EBITDA margin was approximately 7.6% in 2025.

• Specialty sales rose 10%, driven by a joint development agreement and mosquito vector solutions.

Outlook and guidance

• 2026 adjusted EBITDA is forecasted at $44–$48 million on sales of $530–$550 million.

• Targeting long-term EBITDA margin of 15% and 4–6% compound annual sales growth.

• Anticipates free cash flow positive in 2026, with CapEx in the $5–$10 million range.

• Plans to launch at least 25 new products in North America by 2031, aiming for $100 million in additional annual revenue by 2030–2031.

• Strategic focus on increasing volumes and new products is expected to drive sales and profitability.